Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis +54 more
wiley +1 more source
Mercury and methylmercury distribution in tissues of sculpins from the Bering Sea. [PDF]
Harley J +5 more
europepmc +1 more source
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth +8 more
wiley +1 more source
Stable Isotope Composition of Skin Layers Confirms Trophic Differentiation of Baird's and Sato's Beaked Whales (Berardius spp.) in the Western North Pacific. [PDF]
Filatova OA +7 more
europepmc +1 more source
Cold Regime interannual variability of primary and secondary producer community composition in the southeastern Bering Sea. [PDF]
Stauffer BA, Miksis-Olds J, Goes JI.
europepmc +1 more source
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos +15 more
wiley +1 more source
The effects of a constructed closure of the Bering Strait on AMOC tipping behavior. [PDF]
Soons J, Dijkstra HA.
europepmc +1 more source
Tocilizumab for severe and refractory mucous membrane pemphigoid
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt +20 more
wiley +1 more source
Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran +2 more
wiley +1 more source
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern +14 more
wiley +1 more source

